mRNA-LNP Vaccines

Lipid nanoparticles (LNPs) are typically composed of ionizable cationic lipids (ICLs), helper lipids, cholesterol, and polyethylene glycol (PEG) lipids. LNPs have become prominent non-viral carriers for mRNA delivery in clinical applications. By encapsulating mRNA within a lipid core, LNPs protect it from degradation, enhance cellular uptake, and promote cytoplasmic release upon entry into target cells.

mRNA–LNP therapy is characterized by precise targeting, high delivery efficiency, and a favorable safety profile, which make it a promising therapeutic approach for various diseases.

• China's sole breakthrough patent for core bottleneck technologies.
• Breaking global patent barriers. Enabling universal LNP platforms. Driving worldwide commercialization.
• Patents granted in US, Russia, Japan, Australia, South Korea & New Zealand.